These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 15329202

  • 1. [Tumor necrosis factor related apoptosis-inducing ligand induces apoptosis and sensitizes resistant hepatic cancer cells to chemotherapy].
    He SQ, Chen XP, Zhang WG, Wang HP, Wang Q.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):456-9. PubMed ID: 15329202
    [Abstract] [Full Text] [Related]

  • 2. [Chinese medicine Extractum trametes robiniophila murr augment tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in human hepatic cancer cell lines].
    Chen XP, He SQ, Zhao X, Huang ZY, Li CH.
    Zhonghua Wai Ke Za Zhi; 2005 Dec 01; 43(23):1524-7. PubMed ID: 16412290
    [Abstract] [Full Text] [Related]

  • 3. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B.
    Clin Cancer Res; 2001 Dec 01; 7(12):3874-83. PubMed ID: 11751478
    [Abstract] [Full Text] [Related]

  • 4. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Yagita H, Monden M.
    Clin Cancer Res; 2004 Dec 01; 10(23):7884-95. PubMed ID: 15585621
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Synergistic effect of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and doxorubicin on human colon cancer SW480 cells].
    Xu LH, Deng CS, Zhu YQ, Liu SQ.
    Ai Zheng; 2003 Aug 01; 22(8):816-20. PubMed ID: 12917026
    [Abstract] [Full Text] [Related]

  • 10. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
    Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, Bitzer M.
    Cancer Res; 2003 May 15; 63(10):2369-72. PubMed ID: 12750253
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand.
    Reddy RM, Tsai WS, Ziauddin MF, Zuo J, Cole GW, Maxhimer JB, Fang B, Schrump DS, Nguyen DM.
    J Thorac Cardiovasc Surg; 2004 Dec 15; 128(6):883-91. PubMed ID: 15573073
    [Abstract] [Full Text] [Related]

  • 15. 1-Methoxy-canthin-6-one induces c-Jun NH2-terminal kinase-dependent apoptosis and synergizes with tumor necrosis factor-related apoptosis-inducing ligand activity in human neoplastic cells of hematopoietic or endodermal origin.
    Ammirante M, Di Giacomo R, De Martino L, Rosati A, Festa M, Gentilella A, Pascale MC, Belisario MA, Leone A, Turco MC, De Feo V.
    Cancer Res; 2006 Apr 15; 66(8):4385-93. PubMed ID: 16618764
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Potential and caveats of TRAIL in cancer therapy.
    Held J, Schulze-Osthoff K.
    Drug Resist Updat; 2001 Aug 15; 4(4):243-52. PubMed ID: 11991679
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.